<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04814030</url>
  </required_header>
  <id_info>
    <org_study_id>B2021-060</org_study_id>
    <nct_id>NCT04814030</nct_id>
  </id_info>
  <brief_title>Transarterial Infusion of PD-1 Antibody Plus TACE-HAIC for Unresectable HCC: a Single-arm, Phase 2 Clinical Trial</brief_title>
  <acronym>AIPD-1</acronym>
  <official_title>Transarterial Infusion of PD-1 Antibody Plus Chemoembolization and FOLFOX-based Chemtherapy for Unresectable BCLC C Stage HCC: a Single-arm, Phase 2 Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hepatocellular carcinoma (HCC) is a common disease in East Asia. Less than 20% of newly&#xD;
      diagnosed patients can undergo radical resection. For those with unresectable BCLC C stage,&#xD;
      transarterial chemotherapy and targeted therapy are recommend to prolong survival. Recently,&#xD;
      FOLFOX (Oxaliplatin and 5-fluorouracil) based hepatic artery infusion chemotherapy (HAIC)&#xD;
      exhibited high response rate for unresectable HCC. Transartery infusion of agents provide&#xD;
      promising outcome when compared systemic infusion. Furthermore, our pilot study showed TACE&#xD;
      combined HAIC (TACE-HAIC) had better tumor response, with low progression disease rate.&#xD;
      Whether TACE-HAIC plus hepatic artery infusion PD-1 antibody would improve survival for&#xD;
      unresectalbe BCLC C stage patients is still unknown. A single arm, phase 2 clinical trial is&#xD;
      aimed to answer this question.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Trans hepatic arterial infusion of PD-1 antibody, chemoembolization and FOLFOX-based chemotherapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate</measure>
    <time_frame>12 month</time_frame>
    <description>defined as the sum of complete responses (CRs) and partial responses (PRs) over a specified time period</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>AIPD-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trans hepatic artery infusion of PD-1 antibody, chemoembolization, FOLFOX-based infusion chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 inhibitor</intervention_name>
    <description>Transarterial hepatic chemoembolization and FOLFOX-based infusion</description>
    <arm_group_label>AIPD-1</arm_group_label>
    <other_name>TACE-HAIC</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  BCLC C stage with unresectable diseasehigh-recurrence risk factor;&#xD;
&#xD;
          -  Child-Pugh A or B (7 score) liver function;&#xD;
&#xD;
          -  Anticipated survival more than 3 moths&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant woman or sucking period;&#xD;
&#xD;
          -  With other malignant cancer;&#xD;
&#xD;
          -  Received anti-HCC therapy before this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jiliang Qiu</last_name>
    <phone>862087343114</phone>
    <email>qiujl@sysucc.org.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xuzhi Pan</last_name>
    <phone>862087343009</phone>
    <email>kyk@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yunfei Yuan</last_name>
      <phone>862087343118</phone>
      <email>yuanyf@sysucc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 23, 2021</study_first_submitted>
  <study_first_submitted_qc>March 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2021</study_first_posted>
  <last_update_submitted>April 21, 2021</last_update_submitted>
  <last_update_submitted_qc>April 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yunfei Yuan</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

